Loading
If a drug relies on one marker, the tumour can survive by dropping it. A drug that recognises two markers at once makes that escape harder.
Bispecific ADCs binding two tumour antigens can retain binding and internalisation when one antigen is lost, and may improve selectivity where either antigen alone is present on normal tissue. Several bispecific ADCs are in clinical development. The proposal is to test the antigen-escape hypothesis explicitly by comparing a bispecific ADC with its monospecific parent and measuring antigen status at progression.
Shares Bispecific ADC, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Antibody-drug conjugate (ADC).
Shares Bispecific ADC, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Antibody-drug conjugate (ADC).
Shares Bispecific ADC, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Antibody-drug conjugate (ADC).
Shares Bispecific ADC, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Antibody-drug conjugate (ADC).
Shares Bispecific ADC, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Antibody-drug conjugate (ADC).
Shares Bispecific ADC, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Antibody-drug conjugate (ADC).
Shares Bispecific ADC, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Antibody-drug conjugate (ADC).
Shares Bispecific ADC, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/